Fusion proteins comprising a tie2 binding domain

Fusion proteins targeting Tie2 and soluble ligands like TNF-a, IL-23, or C5a are developed to stabilize blood vessels by internalization and degradation, addressing the inefficiencies of existing treatments and improving tumor oxygenation and drug delivery.

WO2026142996A1PCT designated stage Publication Date: 2026-07-02INGENIA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
INGENIA THERAPEUTICS INC
Filing Date
2025-12-22
Publication Date
2026-07-02

AI Technical Summary

Technical Problem

Existing anti-Ang2 antibodies and direct Tie2 activators have shown insufficient efficacy in treating vascular abnormalities and cancer, while existing Tie2 activators have short half-lives and unstable physicochemical properties, and small molecule inhibitors activate other receptors, leading to inefficiencies in normalizing pathologic blood vessels.

Method used

Development of fusion proteins that bind both Tie2 and soluble target ligands, forming a complex that is internalized and degraded within cells, specifically targeting TNF-a, IL-23, or C5a, to normalize blood vessels and degrade these ligands.

Benefits of technology

The fusion proteins effectively stabilize blood vessels by internalizing and degrading soluble ligands, improving oxygen delivery and drug penetration in tumors, and reducing vascular leakage, thus enhancing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000020_0001_TABLE
    Figure IMGF000020_0001_TABLE
  • Figure IMGF000021_0001_TABLE
    Figure IMGF000021_0001_TABLE
  • Figure IMGF000022_0001_TABLE
    Figure IMGF000022_0001_TABLE
Patent Text Reader

Abstract

The present disclosure refers to fusion proteins having an antibody against Tie2 or antigen-binding fragment thereof and a soluble target ligand binding domain that binds TNFα, IL-23, VEGF-A, or C5a. The present disclosure also provides methods for making the fusion proteins, and pharmaceutical compositions and methods for preventing or treating angiogenic diseases or regulating angiogenesis, endothelial signaling, inflammation, and / or autoimmune diseases, utilizing the fusion proteins.
Need to check novelty before this filing date? Find Prior Art